



NEWS RELEASE

FIRST PATIENTS TREATED IN DERMAGOLD® AND LITHOGOLD® STUDIES

April 27, 2006 (Woodstock, Georgia) – Tissue Regeneration Technologies, LLC (TRT) announced that today it treated its first diabetic foot ulcer patient with the DermaGold® MultiWave™ device under FDA clinical trials. The treatment was performed at Georgetown University Hospital in Washington, DC by Dr. John Steinberg, an attending physician at Georgetown University Hospital and Assistant Professor in the Department of Surgery at Georgetown University School of Medicine.

“The device technology is quite simple to use and was easy to apply in the treatment room. The concept certainly has caught our attention and we look forward to seeing the clinical trial data in the very near future. The impact on wound care could be very substantial,” stated Steinberg.

“This is the first step in our goal to reduce by at least 50% the 85,000 amputations that are performed annually due to diabetic ulcers and to offer hope to a patient population that, until now, has been poorly served by modern technology. It is also our fervent belief that a small abrasion on the foot should not become a death sentence for diabetic patients, but unfortunately, too often it does. We think our technology will change that, giving diabetic patients a new lease on life” stated John Warlick, Tissue Regeneration Technologies’ CEO and President.

The second study site, Calvary Hospital in Bronx, New York, is expected to begin treating patients in May, with the remaining eight study sites treating patients within 120 days. The study will include 200 patients: 100 in the control group and 100 in the treatment group. Treatment and complete follow-up on all 200 patients are anticipated within twelve months.

Furthermore, the Company announced that today it also commenced patient treatments with its LithoGold® lithotripsy system under an FDA 510(k) clinical trial. Under this study, TRT will be required to treat 20 patients and provide one week of follow-up data on each. “We expect to submit our data to the FDA by late May and hope to have approval to sell LithoGold devices by mid-year,” said Warlick. The LithoGold utilizes exclusive, patented technology to ensure more consistent shockwaves than any other lithotripsy device. It also offers the largest treatment area and deepest penetration depth of any lithotripter on the market and is modular, transportable and highly versatile. “Our LithoGold was aptly named because it sets the new Gold Standard in kidney and ureter stone treatment,” stated Warlick.

About Tissue Regeneration Technologies

Tissue Regeneration Technologies is a leading-edge health care company that believes in “doing well by doing good.” Its state-of-the-art medical devices utilize MultiWaves™ (Pulsed Acoustic Wave technology) for non-invasive treatment of chronically infected wounds, periodontal

indications, ischemic heart disease and orthopedic indications such as tendinopathies, osteoarthritis and avascular conditions of the bones. TRT is headquartered in and operates its urology division, Shockwave Technical Service (STS), from Woodstock, Georgia. STS provides technical service, repair and maintenance for medical devices. Medical device production is handled by TRT's manufacturing subsidiary, MTS Europe GmbH, located in Konstanz, Germany. TRT's devices are currently distributed in 16 countries throughout North America, Europe, Asia, Africa and South America. For more information, please visit www.trtlc.com.

Tissue Regeneration Technologies, LLC
110 Arnold Mill Park, Suite 400
Woodstock, Georgia 30188
Tel: (770) 966-1315 / (877) 966-1315
Fax: (770) 592-8910
Web: www.trtlc.com

Contact:

John Warlick, CEO & President

jwarlick@trtlc.com

(770) 966-1315

or

Julie Dodd, VP, Corporate Communications

jdodd@trtlc.com

(770) 966-1315